Findings text and was not extracted in this pass. Drift signals here cannot be attributed to specific health plans.
Cell value is overturn rate. Color intensity scales with rate (deeper green = more frequently overturned). Empty cells = no IMR cases for that treatment in that year. Treatments restricted to those with n≥10 total across the window.
| Treatment | From | To | Δpp | From rate (n) | To rate (n) |
|---|---|---|---|---|---|
| Other | 2005–2007 | 2008–2010 | +30.0 | 3.3% (n=30) | 33.3% (n=15) |
| TMS | 2008–2010 | 2011–2013 | +17.5 | 26.3% (n=19) | 43.8% (n=105) |
The TMS shift correlates with FDA-cleared TMS device proliferation and post-2010 payer pushback. The "Other" jump is partly classification noise — small-cell instability with n=15 in the second window.
| Rank | Treatment Subcategory | N | Overturn Rate |
|---|---|---|---|
| 1 | TMS | 145 | 44.1% |
| 2 | Other | 111 | 18.0% |
| 3 | Lab Work | 28 | 3.6% |
| 4 | Applied Behav Analysis | 24 | 83.3% |
| 5 | Genetic/Genomic Test | 21 | 19.0% |
other, not upheld. Partial reversals not credited as overturns.analyses/ca_imr_data/